CNG-β3 inhibitors belong to a distinct chemical class designed to specifically target and modulate the activity of the CNG-β3 subunit, which is a component of cyclic nucleotide-gated (CNG) ion channels. These ion channels are essential for the transduction of sensory signals in various tissues, including the retina and the olfactory epithelium. By inhibiting CNG-β3, these compounds aim to interfere with the normal functioning of the ion channels, which are responsible for opening and closing in response to cyclic nucleotide binding. The development of CNG-β3 inhibitors involves advanced research methodologies, computational techniques, and experimental screening. Scientists may use a variety of approaches, such as structure-based drug design, high-throughput screening, virtual screening, pharmacophore modeling, and natural product-based screening. These strategies help identify inhibitors that interact with specific regions of the CNG-β3 protein, disrupting its role in the modulation of ion channel activity. Once inhibitors are identified, researchers conduct further studies to optimize their chemical structure, potency, and selectivity. This includes performing Structure-Activity Relationship (SAR) studies to understand the relationship between the chemical structure of the inhibitors and their inhibitory effects on CNG-β3.
Functional assays, such as patch-clamp electrophysiology, are utilized to validate the inhibitory activity of these compounds on the ion channel function in vitro. Additionally, in vivo studies may be performed to explore the efficacy of CNG-β3 inhibitors in animal models, providing insights into their effects on sensory signal transduction processes. The study of CNG-β3 inhibitors holds promise for advancing our understanding of the molecular mechanisms underlying sensory signal transduction in the visual and olfactory systems. By exploring the interactions between these inhibitors and CNG-β3, researchers aim to contribute to the broader understanding of ion channel regulation and cellular signaling processes.
SEE ALSO...
Items 11 to 14 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
This potent inhibitor of RNA polymerase II could selectively inhibit the elongation phase of mRNA synthesis, leading to decreased levels of CNGB3 transcripts. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram can chelate copper, possibly leading to downregulation of multiple genes including CNGB3. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
By binding to retinoic acid receptors, retinoic acid can alter the transcription of genes involved in cell differentiation and proliferation, potentially decreasing CNGB3 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which could lead to a generalized decrease in protein synthesis, potentially including the downregulation of CNGB3 protein levels. | ||||||